|
gptkbp:instanceOf
|
gptkb:antiviral_drug
gptkb:protease_inhibitor
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J05AE12
|
|
gptkbp:CASNumber
|
394730-60-0
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:eliminationHalfLife
|
3.4 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C27H45N5O5
|
|
gptkbp:KEGGID
|
D08913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Victrelis
|
|
gptkbp:MeSH_ID
|
C526747
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL1077510
11954377
DB08873
|
|
gptkbp:retired
|
availability of more effective treatments
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
dysgeusia
|
|
gptkbp:synonym
|
SCH 503034
|
|
gptkbp:target
|
gptkb:NS3/4A_serine_protease
|
|
gptkbp:UNII
|
6HR859B464
|
|
gptkbp:usedFor
|
treatment of hepatitis C
|
|
gptkbp:withdrawn
|
2015
|
|
gptkbp:bfsParent
|
gptkb:SARS-CoV-2_main_protease
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Boceprevir
|